AlphaQuest LLC Sells 43,013 Shares of Tyra Biosciences, Inc. $TYRA

AlphaQuest LLC cut its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 58.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,060 shares of the company’s stock after selling 43,013 shares during the period. AlphaQuest LLC’s holdings in Tyra Biosciences were worth $421,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. HighVista Strategies LLC increased its holdings in Tyra Biosciences by 4.3% during the 2nd quarter. HighVista Strategies LLC now owns 24,962 shares of the company’s stock worth $239,000 after acquiring an additional 1,021 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Tyra Biosciences by 14.5% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock valued at $126,000 after purchasing an additional 1,668 shares in the last quarter. Federated Hermes Inc. raised its position in shares of Tyra Biosciences by 586.3% in the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock worth $30,000 after buying an additional 1,841 shares in the last quarter. American Century Companies Inc. increased its stake in Tyra Biosciences by 23.1% in the 2nd quarter. American Century Companies Inc. now owns 28,854 shares of the company’s stock worth $276,000 after acquiring an additional 5,423 shares during the last quarter. Finally, Intech Investment Management LLC raised its holdings in shares of Tyra Biosciences by 46.5% in the 2nd quarter. Intech Investment Management LLC now owns 19,919 shares of the company’s stock valued at $191,000 after acquiring an additional 6,322 shares in the last quarter. 84.14% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Wednesday, January 21st. Piper Sandler lifted their price objective on shares of Tyra Biosciences from $33.00 to $42.00 and gave the stock an “overweight” rating in a report on Friday, January 23rd. Wedbush raised their price target on Tyra Biosciences from $30.00 to $37.00 and gave the company an “outperform” rating in a research report on Tuesday, December 16th. Barclays initiated coverage on Tyra Biosciences in a report on Tuesday, January 27th. They issued an “overweight” rating for the company. Finally, Jefferies Financial Group increased their price objective on Tyra Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Tyra Biosciences presently has an average rating of “Moderate Buy” and an average price target of $37.17.

Tyra Biosciences Stock Up 5.2%

Tyra Biosciences stock opened at $31.00 on Friday. The firm has a fifty day simple moving average of $26.81 and a two-hundred day simple moving average of $18.20. Tyra Biosciences, Inc. has a twelve month low of $6.42 and a twelve month high of $32.44. The company has a market capitalization of $1.65 billion, a PE ratio of -16.58 and a beta of 1.07.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.50) EPS for the quarter, hitting the consensus estimate of ($0.50). As a group, equities analysts expect that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Tyra Biosciences news, Director Robert J. More sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $25.00, for a total value of $250,000.00. Following the completion of the sale, the director owned 3,823,425 shares in the company, valued at approximately $95,585,625. The trade was a 0.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 15.20% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.